<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Oyama, Junichi</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Incretins in Cardiovascular Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-8</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the potential benefits of incretin therapies in patients with cardiovascular disease. The 2 main incretin hormones are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide. GLP-1 exerts beneficial effects on myocardial and endothelial function by inhibiting upregulation of reactive oxygen species and vascular cell adhesion molecule-1 mRNA in endothelial cells.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>